Skip to main content
. 2015 May 5;6(16):14399–14412. doi: 10.18632/oncotarget.3882

Figure 1. The expression of ZEB1 and BMP-inhibitors correlates with breast cancer bone metastasis.

Figure 1

A. Stable shRNA mediated knockdown of ZEB1 in MDA-MB-231 results in downregulation of the BMP-inhibitors NOG, FST and CHRDL1 relative to control clone shCtrl #1 on mRNA and protein level, measured by qRT-PCR and western blot analysis. qRT-PCR data are represented as mean +SD. B. The expression of ZEB1 and NOG (left), as well as ZEB1 and FST (right) is significantly correlated in metastatic samples from bone, lung and brain of breast cancer patients (GSE14020). C. Comparison of mRNA expression levels of bone metastases to other metastatic sites in a set of samples from bone, lung and brain metastases of breast cancer patients (GSE14020) reveals higher expression of ZEB1, NOG and FST in bone metastases. Boxplots are depicted according to Tukey. D. Heatmap showing the correlated expression of ZEB1, NOG and FST in metastatic samples (GSE14020). The ER status is depicted with + or −. The outlier values for FST and NOG that were observed in the boxplots in C were excluded and depicted as grey boxes with *. The sites of metastases, bone, brain and lung, are indicated in the top row in dark blue, orange and light blue, respectively.